Controlled treatment holidays, different dosing regimens as well as extended interval dosing (EID) were proposed as strategies to reduce PML risk while maintaining efficacy of NAT therapy (8–13). This evidence concerns the gene BRD2 and progressive multifocal leukoencephalopathy.